OClawVPS.com
Illumina
Edit

Illumina

http://www.illumina.com/
Last activity: 03.04.2026
Active
Categories: AnalyticsDevelopmentDiagnosticsHealthTechHumanMarketPlatformResearchTechnologyTools
Illumina is a global company that develops innovative array-based solutions for DNA, RNA, and protein analysis. By empowering the genetic analysis research of our customers, our tools make a difference in disease research, drug development, and the development of molecular tests in the clinic.
Likes
24.21K
Followers
269.75K
Website visits
878.1K /mo.
Mentions
326
Location: Japan, Minato
Employees: 5001-10000
Phone: +1 858-202-4500
Total raised: $500K
Founded date: 1998

Investors 8

Funding Rounds 1

DateSeriesAmountInvestors
07.06.2022Grant$500K-

Mentions in press and media 326

DateTitleDescription
03.04.2026Assembling Over 1,000 Human Genomes Affordably: New Method Powers Medicine's FutureHANGZHOU, China, April 3, 2026 /PRNewswire/ -- A research team led by Zhen-Xing Endowed Professor Jian Yang at the School of Life Sciences, Westlake University, together with collaborators, published their latest findings in Nature on April...
27.02.2026Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected MultiomicsTruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow, and the new AGBT data demonstrates its accuracy in detecting rare genetic diseases 40% increase in output to 35 billion reads, up to Q70 quality sc...
26.02.2026Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomicsAt AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced new customer breakthroughs in oncology powered by Illumina's s...
25.02.2026Illumina launches TruPath Genome, setting a new standard in genomic insightTruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease Broad Clinical Labs is among first to adopt product,...
24.02.2026Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded val...
12.01.2026Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership TeamT. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors FREMONT, Calif., ...
18.12.2025Bringing rapid, lab-grade diagnostics to the pond side-
12.11.2025Hepta Unveils AI Liquid Biopsy for Chronic DiseaseHepta secures $6.7M. It pioneers AI-driven liquid biopsy for chronic diseases, starting with MASH. Its transformer AI platform analyzes cell-free DNA epigenomes. This delivers unparalleled precision in diagnosis. The non-invasive blood test...
10.11.2025Hepta Emerges from Stealth with $6.7M to Pioneer AI-Driven Chronic Disease Liquid BiopsyWhat You Should Know: – Hepta, a biotechnology company focused on diagnosing chronic disease, has emerged from stealth announcing $6.7M in seed funding co-led by Felicis Ventures and Illumina Ventures, with participation from SeaX Ventures,...
06.11.2025Hepta: $6.7 Million Seed Funding Closed To Advance Liquid Biopsy-Based AI Diagnostics For Chronic Liver DiseaseHepta, a biotechnology company developing a transformer-based artificial intelligence platform to analyze the cell-free DNA epigenome, has emerged from stealth with $6.7 million in seed funding. The round was led by Felicis Ventures and Ill...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In